Benefits in Myasthenia Gravis Extend to 52 Weeks With Inebilizumab

(MedPage Today)-San Diego-Pyplizna (Uplizna) improving the function and reducing the severity of the disease for up to 52 weeks in the generalized muscular (GMG) patients who were ACR receptors (ACHR), data from mint …